Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q2 2026 › vs Q1 2026
Kiniksa Pharmaceuticals International (KNSA) Q2 2026 vs Q1 2026 (quarter over quarter)
Kiniksa Pharmaceuticals International's revenue rose $29.3M (+14%) from $214M in Q1 2026 to $244M in Q2 2026. Operating margin 11.2% against 13.7% (-2.5 pts).
Kiniksa Pharmaceuticals International, Q2 2026: revenue $244M (+55% year over year), operating margin 11.2%, net earnings $25.4M, operating cash flow $47.2M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 11.2% | 13.7% | -2.5 pts |
| Net margin | 10.4% | 10.5% | -0.1 pts |
| Free cash flow margin | 19.1% | 23.4% | -4.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $244M | $214M | $29.3M | +14% |
| Other income, net | $4.0M | $3.4M | $537K | +16% |
| Operating profit | $27.2M | $29.3M | −$2.1M | -7% |
| Costs & expenses | $216M | $185M | $31.4M | +17% |
| Pre-tax earnings | $31.1M | $32.7M | −$1.5M | -5% |
| Cost of revenue | $23.6M | $20.8M | $2.8M | +13% |
| Research & development | $40.9M | $27.5M | $13.4M | +49% |
| SG&A | $63.9M | $61.2M | $2.7M | +4% |
| Other operating costs | $88.1M | $75.6M | $12.5M | +17% |
| Net earnings | $25.4M | $22.6M | $2.8M | +13% |
| Income tax | $5.7M | $10.1M | −$4.4M | -43% |
| Depreciation & amortization | $472K | $468K | $4K | +0.9% |
| Share-based compensation | $11.6M | $10.1M | $1.6M | +16% |
| Working capital & other | $9.7M | $17.1M | −$7.4M | -43% |
| Operating cash flow | $47.2M | $50.2M | −$3.0M | -6% |
| Free cash flow (OCF − capex) | $46.5M | $50.0M | −$3.5M | -7% |
| Capital expenditures | $663K | $161K | $502K | +312% |
Questions
How much did Kiniksa Pharmaceuticals International's revenue grow quarter over quarter in Q2 2026?
Kiniksa Pharmaceuticals International's revenue rose $29.3M (+14%) from $214M in Q1 2026 to $244M in Q2 2026. Operating margin 11.2% against 13.7% (-2.5 pts).